Trial Profile
Facilitated Immunoglobulin Administration Registry and Outcomes Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions
- Acronyms FIGARO
- Sponsors GWT-TUD GmbH
- 27 Jul 2021 Status changed from active, no longer recruiting to completed.
- 17 Jun 2021 Interim results (n=156; as of 2 Feb 2021) presented at the 26th Congress of the European Haematology Association
- 01 Feb 2021 Planned number of patients changed from 100 to 154.